Market access of Spinraza (Nusinersen) for spinal muscular atrophy: Intellectual property rights, pricing, value and coverage considerations

Gene Therapy

Volumn 24, Issue 9, 2017, Pages 539-541

  Simoens, S ^a   Huys, I ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NUSINERSEN; ORPHAN DRUG; OLIGONUCLEOTIDE;

DRUG COST; DRUG MARKETING; HEALTH CARE ACCESS; HUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SOCIAL PARTICIPATION; SPINAL MUSCULAR ATROPHY; ECONOMICS; GENE THERAPY;

GENETIC THERAPY; HUMANS; INTELLECTUAL PROPERTY; MUSCULAR ATROPHY, SPINAL; OLIGONUCLEOTIDES;

EID: 85032491162     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.79     Document Type: Review

References (23)

1. Pearn J. Classification of spinal muscular atrophies. Lancet 1980; 1: 919-922.
2. Burglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud C et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996; 32: 479-482.
3. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371: 2120-2133.
4. ATMP Regulation. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.
5. European Medicines Agency. First medicine for spinal muscular atrophy. April 2017. Availavle at: http://www.ema.europa.eu/ema/index.jsp?curl= pages/news- and-events/news/2017/04/news-detail-002735.jsp&mid =WC0b01ac058004d5c1.
6. Picchi A. The cost of Biogen's new drug: 750000 per patient. CBS News 29 December 2016. Available at http://www.cbsnews.com/news/the-cost-of-biogensnew-drug-spinraza-750000-per-patient/.
7. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011; 6: 42.
8. Nace M. FDA approves Biogen's Spinraza (nusinersen) as first approved SMA drug for children, adults. SMA News Today 2016.
9. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010; 9: 921-929.
10. Morrison C. Fresh from the biotech pipeline-2016. Nat Biotechnol 2017; 35: 108-112.
11. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012; 7: 74.
12. Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health 2013; 16: 1163-1169.
13. Garber K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nature Biotechnol 2016; 34: 1002-1003.
14. Cure SMA Report, Winter 2016. Available at: http://www.curesma.org/documents/ support-care-documents/2016-winter-directions.pdf.
15. Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nature Neuroscience 2017; 20: 497-499.
16. Biogen Press Release, 2016. Available at: http://media.biogen.com/press-release/ investor-relations/biogen-and-ionis-pharmaceuticals-report-nusinersen-meets-pri mary-e.n.
17. Ionis Pharmaceuticals, 2016. Available at: http://www.prnewswire.com/newsreleases/ spinraza-nusinersen-approved-in-us-to-treat-broad-range-of-patientswith-spinal-muscular-atrophy-300383512.html.
18. SMA Europe Announcement. Available at: http://www.sma-europe.eu/news/spin raza-community-update-by-biogen-feedback-on-a-call-with-sma-europe/.
19. Vandenbroeck P, Raeymakers P, Wickert R, Becher K, Goossens J, Cleemput I et al. Future scenarios about drug development and drug pricing. Health Services Research (HSR) Belgian Health Care Knowledge Centre (KCE): Brussels, 2016, KCE Reports 271. Available at: https://kce.fgov.be/publication/report/future-scenariosabout-drug-development-and-drug-pricing#.WLKeSrGZOCQ.
20. TRIPS, Agreement on trade-related aspects of intellectual property rights, 1994. Available at: https://www.wto.org/english/docs-e/legal-e/27-trips.pdf.
21. Anastasaki E, Bradshaw SE, Walker A. An update on market access for advancedtherapy medicinal products in Europe. ISPOR 17th Annual European Congress. ISPOR: Amsterdam, The Netherlands, 2014.
22. Hanna E, Rémuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: current and future perspectives. J Market Access Health Policy 2016; 4: 31036.
23. Lucas F. Performance-based managed entry agreements for medicines: much needed, but not feasible? Value & Outcomes Spotlight 2016; 2: 10-12.